Bibliographic record

Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes

Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack…. New England Journal of Medicine 2019

Document identifier: CEI-BR-044
Series: Bibliographic record
Version: 1.0
Published: 30 Jul 2026
Last reviewed: 30 Jul 2026
Certainty: Not rated

§1Bibliographic record

§1.1Record

Authors: Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsbøll T, Warren ML, Bain SC
Title: Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes
Source: New England Journal of Medicine
Year: 2019
Volume, issue, pages: 381(9):841–851
Digital object identifier: 10.1056/NEJMoa1901118
PubMed identifier: 31185157
Record type: Journal article
Institute identifier: CEI-BR-044

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

Document	Series
Monograph: Semaglutide, oral	Compound monograph
Synthesis: Semaglutide, oral in type 2 diabetes mellitus: effect on the anchor…	Evidence synthesis
Synthesis: Semaglutide, oral in atherosclerotic cardiovascular disease and…	Evidence synthesis
Synthesis: Semaglutide, oral in type 2 diabetes mellitus: tolerability and…	Evidence synthesis
Synthesis: Semaglutide, oral in atherosclerotic cardiovascular disease and…	Evidence synthesis
Synthesis: Semaglutide, oral in type 2 diabetes mellitus: durability of effect	Evidence synthesis
6 citing documents.

§1.3Subject tags

oral-semaglutide cardiovascular PIONEER

Compound Evidence Institute · CEI-BR-044 · https://compoundevidence.com/bibliography/husain2019/ · retrieved 30 July 2026